Kinase Inhibitor [EPC]

300764 reported adverse events

Drugs of this class: SIROLIMUS EVEROLIMUS PALBOCICLIB AXITINIB ERLOTINIB HYDROCHLORIDE ABEMACICLIB ACALABRUTINIB AFATINIB BRIGATINIB CERITINIB COPANLISIB

These side effects are most commonly reported by patients taking drugs of the Kinase Inhibitor [EPC] class:

# Side effect Count
0 DEATH 32474
1 FATIGUE 26266
2 DIARRHOEA 24679
3 NAUSEA 17893
4 OFF LABEL USE 15327
5 RASH 12708
6 MALIGNANT NEOPLASM PROGRESSION 11774
7 DECREASED APPETITE 11066
8 DYSPNOEA 11016
9 ASTHENIA 10976
See all common reactions for Kinase Inhibitor [EPC]

Drugs of the Kinase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EGFR GENE MUTATION 150 0.8380
1 CYTOGENETIC ANALYSIS ABNORMAL 300 0.5226
2 CARBOHYDRATE ANTIGEN 15-3 INCREASED 150 0.4573
3 NEOPLASM PROGRESSION 8379 0.4288
4 TRANSPLANT DYSFUNCTION 475 0.4063
5 CHRONIC MYELOID LEUKAEMIA RECURRENT 127 0.4045
6 ACQUIRED GENE MUTATION 254 0.3741
7 METASTASES TO PLEURA 189 0.3351
8 TUMOUR MARKER INCREASED 824 0.3320
9 NON-SMALL CELL LUNG CANCER 699 0.3186
See all enriched reactions for Kinase Inhibitor [EPC]